1. Stanford J.L., Stephenson R.A., Coyle L.M. et al. Prostate Cancer Trends 1973 - 1995. SEER Program, National Cancer Institute, NIH Pub.; 99 - 4543, Bethesda: MD; 1999.

2. Steinberg G.D., Carter B.S., Beaty T.H. et al. Family history and the risk of prostate cancer. Prostate 1990; 17: 337 - 437.

3. Stewart R.W. et al. Screening for prostate cancer. Semin Oncol 2017; 44: 47.

4. Tan D.S. et al. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin Oncol 2016; 34: 91.

5. Denis L., Morton M.S., Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol 1999; 35: 377 - 387.

6. Jansson K.F. et al. Concordance of tumor differentiation among brothers with prostate cancer. Eur Urol 2012; 62: 656.

7. Key T.J. Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition. Recent Results Cancer Res 2014; 202: 39.

8. Alexander D.D. et al. Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids (LComega-3PUFA) and Prostate Cancer. Nutr Cancer 2015; 67: 543.

9. Lippi G. et al. Fried food and prostate cancer risk: systematic review and meta-analysis. Int J Food Sci Nutr 2015; 66: 587.

10. Chen P. et al. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015; 94: e1260.

11. Ilic D. et al. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 2012; 72: 269.

12. Bylsma L.C. et al. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J 2015; 14: 125.

13. Kristal A.R. et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014; 23: 1494.

14. Nyame Y.A. et al. Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol 2016; 34: 1345.

15. Lippman S.M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39.

16. Kramer B.S. et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009; 27: 1502.

17. Andriole G.L. et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192.

18. Thompson I.M. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215.

19. Haider A. et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow up of 3 registries. J Urol 2015; 193: 80.

20. Zhou C.K. et al. Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 2016; 183: 210.

21. Lian W.Q. et al. Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies. Med Sci Monit 2015; 21: 1902.

22. Rao D. et al. Does night-shift work increase the risk of prostate cancer? А systematic review and meta-analysis. Onco Targets Ther 2015; 8: 2817.

23. Raslau D. et al. The risk of prostate cancer in pilots: a meta-analysis. Aerosp Med Hum Perform 2015; 86: 112.

24. Islami F. et al. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014; 66: 1054.

25. Zhang X.L. et al. Vasectomy and the risk of prostate cancer: a meta-analysis of cohort studies. Int J Clin Exp Med 2015; 8: 17977.

26. Huang T.B. et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014; 46: 1715.

27. Bhindi B. et al. The impact of the use of aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. Urology 2014; 84: 1073.

28. Lin S.W. et al. Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. Int J Cancer 2012; 131: E1015.

29. Pabalan N. et al. Association of male circumcision with risk of prostate cancer: a meta-analysis. Prostate Cancer Prostatic Dis 2015; 18: 352.

30. Rider J.R. et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016; 70: 974.

31. Pernar C.H. Ebot E.M., Wilson K.M., Mucci L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med 2018 Jan 8. pii: a030361. doi: 10.1101/cshperspect.a030361.

32. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.; 2019.

33. Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.; 2019.

34. Partin A.W., Kattan M.W., Subong E.N.P. et al. Combination of prostatespecific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 227: 1445 - 1451.

35. Partin A.W., Yoo J., Carter H.B. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110 - 114.

36. Partin A.W. et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843.

37. Gosselaar C. et al. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008; 54: 581.

38. Алексеева Г.Н. и др. Сравнительная характеристика диагностической значимости методов обследования пациентов с подозрением на злокачественные новообразования предстательной железы. Тихоокеанский медицинский журнал 2011; 3(45).

39. Epstein J.I., Egevad L., Amin M.B., Delahunt B., Srigley J.R., Humphrey P.A. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016 February; 40(2): 244 - 52. DOI: 10.1097/PAS.0000000000000530.

40. Pedersen K.V., Carlson P., Varenhorst E. et al. Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ 1990; 300: 1041 - 1044.

41. Chodak G.W. Early detection and screening for prostatic cancer. Urology 1989; 34(Suppl. 4): 10 - 12.

42. Thompson I.M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239.

43. Carlsson S. et al. Screening for Prostate Cancer Starting at Age 50 - 54 Years. A Population-based Cohort Study. Eur Urol 2017; 71: 46.

44. Albright F. et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate 2015; 75: 390.

45. Ilic D. et al. Screening for prostate cancer. Cochrane database of systematic reviews 2013; 1.

46. Loeb S. et al. The prostate health index selectively identifies clinically significant prostate cancer. The Journal of urology 2015; 193(4): 1163 - 1169.

47. Hamoen E.H.J. et al. Use of the prostate imaging reporting and data system (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. European urology 2015; 67(6): 1112 - 1121.

48. Crawford E.D., Schutz M.J., Clejan S. et al. The effect of digital rectal examination on prostatespecific antigen levels. JAMA 1992; 267: 2227 - 2228.

49. Oesterling J.E., Jacobsen S.J., Chute C.G. et al. Serum prostate specific antigen in a community based population of healthy men: establishment of age specific reference ranges. JAMA 1993; 270: 860 - 864.

50. Edwards J.E., Moore R.A. Finasteride in the treatment of clinical benignprostatic hyperplasia: A systematic review of randomized trials. BMC Urology 2002; 2: 14.

51. Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283 - 1290.

52. Lodding P., Aus G., Bergdahl S. et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antigen. J Urol 1998; 159: 899 - 903.

53. Dong F. et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180: 150.

54. Loeb S. et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 2015; 67: 619.

55. Benson M.C., Olsson C.A. Prostate specific antigen density - roles in patient evaluation and management. Cancer 1994; 74: 1667 - 1673.

56. Zlotta A.R., Djavan B., Marberger M., Schulman C.C. Prostate specific antigen of the transition zone: a new parameter for prostate cancer prediction. J. Urol 1997; 157: 1315 - 1321.

57. Catalona W.J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542.

58. Catalona W.J., Southwick P.C., Slawin K.M. et al. Comparison of percent free PSA, PSA density and age specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56(2): 255 - 260.

59. Carter H.B. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215.

60. Catalona W.J., Beiser J.A., Smith D.S. Serum free prostatespecific antigen and prostatespecific antigen density measurements for predicning cancer in men with prior negative prostatic biopsies. J Urol 1997; 158: 2162 - 2167.

61. Kattan M.W., Zelefsky M.J., Kupelian P.A. et al. Pretreatment nomogram for predicting the outcome of three dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000; 19: 3352 - 3359.

62. Partin A.W., Kattan M.W., Subong E.N. P. et al. Combination of prostatespecific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 227: 1445 - 1451.

63. Smith J.A., Lange R.A., Janknegt R.A. et al. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J. Urol 1997; 157: 1329 - 1334.

64. Heidenreich, A. Identification of high-risk prostate cancer: role of prostate-specific antigen, PSA doubling time, and PSA velocity. Eur Urol 2008; 54: 976.

65. O'Brie M.F. et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009; 27: 3591.

66. Vickers A.J. et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398.

67. Deras I.L. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587.

68. Hessels D. et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8.

69. Nakanishi H. et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804.

70. Luo Y. et al. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta-analysis. 2014.

71. Hessels D. et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70: 10.

72. De la Calle C. et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men. J Urol 2015; 194: 65.

73. Catalona W.J. et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650.

74. Loeb S. et al. The prostate health index selectively identifies clinically significant prostate cancer. The Journal of urology 2015; 193(4): 1163 - 1169.

75. Liu Y. et al. Prostate health index in predicting the results of prostate biopsy for prostate cancer: a meta-analysis. 2014.

76. Haese A., Graefen M., Steuber T., Becker C., Pettersson K., Piironen T., Noldus J., Huland H., Lilja H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001 Oct 1; 49(2): 101 - 9.

77. Auprich M. et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011; 60: 1045.

78. Wolff J.M., Ittel T.H., Borchers H. et al. Metastatic workup of patients with prostate cancer employing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res 1999; 19: 2653 - 2655.

79. Lee F., TorpPedersen S.T., Siders D.B. et al. Transrectal ultrasound in the diagnosis and staging of prostate cancer. Radiology 1989; 170: 609 - 615.

80. Wang R. et al. Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients. Clin Cancer Res 2017; 23: 3692.

81. https://uroweb.org/guideline/prostate-cancer/#note_158

82. Song J.M. et al. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic Korean men. Yonsei medical journal 2005; 46(3): 414 - 424.

83. Bryant R.J., Sjoberg D.D., Vickers A.J., Robinson M.C., Kumar R., Marsden L., Davis M., Scardino P.T., Donovan J., Neal D.E., Lilja H., Hamdy F.C. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst 2015 Jul; 107(7).

84. Митина Л.А., Казакевич В.И., Степанов С.О. Ультразвуковая онкоурология. М.: Триумф; 2009. 200 с. ISBN 978-5-89392-463-3.

85. Ellis W.J., Chetner M.P., Preston S.D., Brawer M.K. Diagnosis of prostatecarcinoma: the yield of serum prostate specific antigen, digital restal examination, and transrectal ultrasonography. J Urol 1994; 152: 1520 - 1525.

86. Patel U., Rickards D. The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation. Br J Urol 1994; 74(5): 590 - 595.

87. Smeenge M. et al. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int 2012; 110: 942.

88. Bratan F. et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 2013; 23: 2019.

89. Le J.D. et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol 2015; 67: 569.

90. Borofsky S. et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology 2018; 286: 186.

91. Zhang L. et al. A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. European radiology 2017; 27(12): 5204 - 5214.

92. Smith J.A. Jr. et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol 1997; 157: 902.

93. Mitterberger M. et al. The value of three-dimensional transrectal ultrasonography in staging prostate cancer. BJU Int 2007; 100: 47.

94. Sauvain J.L. et al. Value of power doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol 2003; 44: 21.

95. Schnall M.D., Imai Y., Tomaszewski J. et al. Prostate cancer: local staging with endorectal surface coil MR imaging. Radiology 1991; 178: 797 - 802.

96. De Rooij M. et al. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol 2016; 70: 233.

97. Jager G.J. et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996; 166: 845.

98. Mohler J.L., Srinivas S., Antonarakis E.S., Armstrong A.J. et al. Prostate cancer. In: NCCN Guidelines Version 4. 2019.

99. Harisinghani M.G. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491.

100. Hovels A.M. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387.

101. Eifler J.B. et al. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy. The Journal of urology 2011; 185(5): 1661 - 1666.

102. Heck M.M. et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014; 41: 694.

103. Budiharto T. et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011; 60: 125.

104. Van Leeuwen P.J. et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017; 119: 209.

105. Briganti A. et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010; 57: 551.

106. Abuzallouf S. et al. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004. 171: 2122.

107. Shen G. et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014.

108. Shariat S.F. et al. Using biopsy to detect prostate cancer. Rev Urol 2008; 10: 262.

109. Xue J. et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget 2017; 8: 23322.

110. Moldovan P. et al. Accuracy of Elastic Fusion of Prostate Magnetic Resonance and Transrectal Ultrasound Images under Routine Conditions: A Prospective Multi-Operator Study. PLoS One 2016; 11: e0169120.

111. Eichler K. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 1605.

112. Pelzer A.E. et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project. Eur Urol 2005; 48: 916.

113. Davis M., Sofer M., Kim S.S., Soloway M.S. The procedure of transrectalultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. J Urol 2002; 167(2) Pt. 1: 566 - 570.

114. Roberts M.J. et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology 2017; 104: 11.

115. Aron M., Rajeev T.P., Gupta N.P. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study. B J U Int 2000; 85(6): 682 - 685.

116. Grabe M., Bartoletti R., Bjerklund-Johansen T.E. et al. Guidelines on urological infections. Eur Assoc Urol 2015; 50 - 8.

117. Wolf J.S. Jr, Bennett C.J., Dmochowski R.R. et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. Am Urol Assoc 2014; 1 - 45.

118. Yasuda M., Nakane K., Yamada Y. et al. Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy. J Infect Chemother 2014; 20: 631 - 4.

119. Pepdjonovic L. et al. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol 2017; 35: 1199.

120. Aron M., Rajeev T.P., Gupta N.P. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85: 682 - 5.

121. Knobloch R. et al. Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial. Eur Urol 2002; 41: 508.

122. Alavi A.S., Soloway M.S., Vaidya A. et al. Local anesthesia for ultrasound guided prostate biopsy: A prospective randomized trial comparing 2 methods. J Urol 2001; 166(4): 1343 - 1345.

123. Keetch D.W., Catalona W.J., Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 1994; 151(6): 1571 - 1574.

124. Richie J.P. et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 365.

125. Carvalhal G.F. et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999; 161: 835.

126. Ericson K.J. et al. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol 2017; 24: 8714.

127. Epstein J.I. et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 820.

128. Merrimen J.L. et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol 2009; 182: 485.

129. Kronz J.D. et al. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol 2001; 32: 389.

130. Guo C.C. et al. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 2006; 19: 1528.

131. Walz J. et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: 498.

132. Moran B.J. et al. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol 2006; 176: 1376.

133. Cornud F. et al. Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. Radiology 2018; 287: 534.

134. Hegarty J. et al. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database of Systematic Reviews 2010; 11.

135. Linzer D.G. et al. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology 1996; 48: 757.

136. Zigeuner R. et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology 2003; 62: 883.

137. Link R.E., Morton R.A. Indications for pelvic lymphadenectomy in prostatecancer. Urol Clin North Am 2001; 28(3): 491 - 498.

138. Fossati N. et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol 2017; 72: 84.

139. Mattei A. et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53: 118.

140. Studer U.E. et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008; 53: 941.

141. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)): Prostate cancer v.2.2020 (https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf).

142. De Bono et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study//Annals of Oncology. Elsevier 2019; 30: v328 - v329.

143. Chodak G.W., Thisted R.A., Gerber G.S. Results of conservative management of clinically localized prostate cancer. N Eng J Med 1994; 330: 242 - 248.

144. Lu-Yao G.L. et al. Outcomes of localized prostate cancer following conservative management. Jama 2009; 302: 1202.

145. Albertsen P.C., Hanley J.A., Gleason D.F., Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975 - 980.

146. Wilt T.J. et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 2017; 377: 132.

147. Lundgren R. Nordle O., Josefsson K. Immediate estrogen or estramustinephosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: A randomized multicenter study with 15 years of follow-up. The South Sweden Prostate Cancer Study Group. J Urol 1995; 153: 1580 - 1586.

148. Boustead G., Edwards S.J. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU international 2007; 99(6): 1383 - 1389.

149. Bruinsma S.M. et al. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. Nat Rev Urol 2017; 14: 312.

150. Jayadevappa R. et al. Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant). Medicine 2017; 96: 18.

151. Mahran A. et al. Younger Men With Prostate Cancer Have Lower Risk of Upgrading While on Active Surveillance: A Meta-analysis and Systematic Review of the Literature. Urology 2018; 121: 11 - 18.

152. Simpkin A.J. et al. Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. European urology 2015; 67(6): 993 - 1005.

153. Tosoian J.J. et al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol 2015; 33: 3379.

154. Albertsen P.C. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol 2015; 25: 232.

155. Bill-Axelson A. et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 2018; 379: 2319.

156. Wilt T.J. et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 2017; 377: 132.

157. Hamdy F.C. et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016; 375: 1415.

158. Yaxley J.W. et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet 2016; 388: 1057.

159. Coughlin G.D. et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018; 19: 1051.

160. Adolfsson J. et al. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol 2007; 52: 1028.

161. Jonsson E. et al. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol 2006; 40: 265.

162. Lu-Yao G.L. et al. Outcomes of localized prostate cancer following conservative management. Jama 2009; 302: 1202.

163. Albertsen P.C. et al. Statistical considerations when assessing outcomes following treatment for prostate cancer. J Urol 1999; 162: 439.

164. Iversen P. et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004.

165. Briganti A. et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61: 480.

166. Gandaglia G. et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol 2017; 72: 632.

167. Cimino S. et al. Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis. Scand J Urol 2017; 51: 345.

168. Roach M. 3rd et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 33.

169. Dell'Oglio P. et al. External validation of the European association of urology recommendations for pelvic lymph node dissection in patients treated with robot-assisted radical prostatectomy. J Endourol 2014; 28: 416.

170. Hinev A.I. et al. Validation of nomograms predicting lymph node involvement in patients with prostate cancer undergoing extended pelvic lymph node dissection. Urol Int 2014.

171. Wit E.M.K. et al. Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. Eur Urol 2017; 71: 596.

172. van der Poel H.G. et al. Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU Int 2017.

173. Bader P. et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 514.

174. Passoni N.M. et al. Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int 2014; 114: 503.

175. Steuber T. et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006; 175: 939.

176. Zorn K.C. et al. External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. J Endourol 2007; 21: 1345.

177. Rud E. et al. Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial? Eur Urol 2015; 68: 487.

178. Engel J. et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010; 57: 754.

179. Kumar S. et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006: CD006019.

180. Shelley M.D. et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer treatment reviews 2009; 35(1): 9 - 17.

181. Ramsay C. et al. Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess 2012; 16: 1.

182. Burkhard F.C. et al. The role of lymphadenectomy in prostate cancer. Nat Clin Pract Urol 2005; 2: 336.

183. Davis J.W. et al. Robot-assisted extended pelvic lymph node dissection (PLND) at the time of radical prostatectomy (RP): a video-based illustration of technique, results, and unmet patient selection needs. BJU Int 2011; 108: 993.

184. Briganti A. et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006.

185. Philippou Y. et al. Comparative Oncologic and Toxicity Outcomes of Salvage Radical Prostatectomy Versus Nonsurgical Therapies for Radiorecurrent Prostate Cancer: A Meta-Regression Analysis. Eur Urol Focus 2016; 2: 158.

186. Chade D.C. et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012; 61: 961.

187. Michalski J., Pisansky T.M., Lawton C.A. et al. Prostate cancer. Eds. Gunderson L.L. et al. Clinical radiation oncology. Third ed. Philadelphia: Elsevier saunders; 2012. P. 1037 - 1097.

188. Nilsson S., B.J., Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncologica 2004; 43(4): 316 - 381.

189. Morris D.E., Emami B., Mauch P.M., Konski A.A., Tao M.L., Ng A.K., Tepper J.E. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: An ASTRO outcomes initiative. International Journal of Radiation Oncology*Biology*Physics 2005; 62(1): 3 - 19. doi: 10.1016/j.ijrobp.2004.07.666.

190. Perez C.A. Prostate. In: Principles and Practice of Radiation Oncology (3rd ed.). C.A. Perez, L.W. Brady (eds.). - Lippincott, Philadelphia; 1998. P. 1583 - 1694.

191. D'Amico A.V., Whittington R., Malkovicz S.B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969 - 974.

192. Perez & Brady's. Principles and Practice of Radiation Oncology (seventh edition)/eds. E.C. Halperin, D.E. Wazer, C.A. Perez, L.W. Brady. Wolters Kluwer, Philadelphia; 2019. Chapter 69 - 70. P. 1560 - 1622.

193. Beckendorf V., Guerif S., Le E. et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80(4): 1056 - 1063.

194. Dearnaley D.P., Jovic G., Syndikus I. et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. The Lancet Oncology 2014; 15(4): 464 - 473.

195. Heemsbergen W.D., Al-Mamgani A., Slot A. et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014; 110(1): 104 - 109.

196. Kuban D.A., Tucker S.L., Dong L. et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70(1): 67 - 74.

197. Kalbasi A., Li J., Berman A.T. et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncology 2015; 1(7): 897 - 906.

198. Michalski J.M., Moughan J., Purdy J. A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer. J Clin Oncol 2015; 33 (supplement 7, abstract 4).

199. Yu T. et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: A meta-analysis of the literatures. PloS one 2016; 11: 5e0154499.

200. Хмелевский Е.В. Рак предстательной железы. В кн. Стандарты лучевой терапии. Под ред. А.Д. Каприна, А.А. Костина, Е.В. Хмелевского. ГЭОТАР-Медиа; 2019. С. 191 - 201.

201. Lawton C.A., Michalski J., El-Naqa I. et al. RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74(2): 383 - 387.

202. Harris V., Staffurs J., Esmail A. et al. Consensus Guidelines and Contouring Atlas for pelvis node delineation in prostate and pelvis node Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2015; 92: 874 - 883.

203. Marks L.B., Ten Haken R.K., Martel M.K. Guest editor"s introduction to QUANTEC: a users guide. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): S1 - 2.

204. Количественный анализ повреждений здоровых органов и тканей при проведении лучевой терапии злокачественных новообразований (проект QUANTEC). Обзор толерантности нормальных тканей: пер. с англ./под общ. ред. С.И. Ткачева. - М.: АМФР; 2015. 250 с.

205. Gay H.A., Barthold H.J., O"Meara E. et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012; 83(3): e353 - 362.

206. Cox J.D., Stetz J.A., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)/J.D. Cox, J. Stetz, T.F. Pajak. Int J Radiat Oncol Biol Phys 1995; 31(5): 1341 - 1346.

207. Pollack A., Walker G., Horwitz E.M. et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013; 31(31): 3860 - 3868.

208. Arcangeli S., Strigari L., Gomellini S. et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84(5): 1172 - 178.

209. Incrocci L., Wortel R.C., Alemayehu W.G. et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016; 17(8): 1061 - 1069.

210. Dearnaley D., Syndikus I., Mossop H. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016; 17(8): 1047 - 1060.

211. Lee W.R., Dignam J.J., Amin M.B. et al. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 2016; 34(20): 2325 - 2332.

212. Seider M.J. et al. Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 2018 Oct; 32(8): 553 - 560. DOI: 10.1007/s12149-018-1278-4.

213. Rutter C.E., Yu J.B., Wilson L.D., Park H.S. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys 2015; 91(3): 548 - 55.

214. Boyer M.J., Salama J.K., Lee W.R. Palliative radiotherapy for prostate cancer. Oncology (Williston Park) 2014 Apr; 28(4): 306 - 12.

215. Merrick G., Butler W., Lief J., Dorsey A. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J RadiatOncolBiolPhys 2000; 47: 121 - 128.

216. Wallner K., Lee H., Wasserman S., Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J RadiatOncolBiolPhys 1997; 37(3): 565 - 9.

217. Hughes S., Wallner K., Merrick G., Miller S., True L.D. Preexisting histologic evidence of prostatitis is unrelated to postimplant urinary morbidity. Int J Cancer 2001; 96 Suppl: 79 - 82.

218. Новиков С.Н., Ощепков В.Н., Канаев С.В. и соавт. Рекомендации по лечению рака предстательной железы с помощью высокомощностной внутритканевой лучевой терапии (брахитерапии). Экспертное совещание, 17 ноября 2016, Москва. Экспериментальная и клиническая урология 2017; 3: 10 - 23.

219. Grann A., Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J RadiatOncolBiolPhys 1998; 40(1): 135 - 138.

220. Merrick G.S., Butler W.M., Wallner K.E., Galbreath R.W., Adamovich E. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004; 64(4): 754 - 759.

221. Implementation of High Dose Rate Brachytherapy in Limited Resource Settings. IAEA; 2015. 116 p.

222. Kollmeier M.A., McBride S., Taggar A., Anderson E., Lin M., Pei X., Weiji S., Voros L., Cohen G., Yamada Y., Zelefsky M.J. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy 2017 Nov - Dec; 16(6): 1091 - 1098. doi: 10.1016/j.brachy.2017.07.013. Epub 2017 Aug 21.

223. Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., van der Poel H.G., van der Kwast T.H., O., Wiegel T., Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017 Apr; 71(4): 630 - 642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

224. James N.D. et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67: 1028.

225. Glass T.R. et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164.

226. Gravis G. et al. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. Eur Urol 2015; 68: 196.

227. Gravis G. et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. Eur Urol 2016; 70: 256.

228. Sweeney C.J. et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015; 373: 737.

229. Hussain M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984.

230. Pagliarulo V. et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61: 11.

231. Seidenfeld J. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000 Apr 4; 132(7): 566 - 77.

232. Kunath F. et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst Rev 2014; 6: CD009266.

233. Albertsen P.C. et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 2014; 65(3): 565 - 573.

234. Margel D. et al. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease. J Urol 2019:101097JU0000000000000384. DOI: 10.1097/JU.0000000000000384.

235. ClinicalTrials.gov Identifier: NCT02663908.

236. Schroder F.H. et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010 Jul; 106(2): 182 - 7.

237. Hosseini S.A. et al. Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis. Medical journal of the Islamic Republic of Iran 2016; 30: 317.

238. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1491.

239. Schmitt B. et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000: CD001526.

240. Akaza H. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437.

241. Rydzewska L.H.M. et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. European journal of cancer 2017; 84: 88 - 101.

242. Niraula S. et al. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013; 31: 2029.

243. Sciarra A. et al. A novel therapeutic option for castration-resistant prostate cancer: after or before chemotherapy? Eur Urol 2014; 65: 905.

244. Botrel T.E. et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol 2014; 14: 9.

245. Brungs D. et al. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014; 17: 105.

246. Magnan S. et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer A Systematic Review and Meta-analysis. JAMA Oncol 2015; 1: 1261.

247. Hussain M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314.

248. Hussain M. et al. Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. J Clin Oncol 2016; 34: 280.

249. Verhagen P.C. et al. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J Urol 2014. 32: 1287.

250. Calais da Silva F. et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol 2014; 66: 232.

251. Abrahamsson P.A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49.

252. Harshman L.C. et al. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol 2018; 36: 376.

253. Nair B. et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002: CD003506.

254. Eisenberger M.A. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036.

255. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1491.

256. Schmitt B. et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000: CD001526.

257. Akaza H. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437.

258. James N.D. et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377: 338.

259. Fizazi K. et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2017; 377: 352.

260. James N.D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163.

261. Gravis G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149.

262. Smith T.J. et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33: 3199.

263. Sydes M.R. et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29: 1235.

264. Wallis C.J.D. et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol 2018; 73: 834.

265. Sun G. et al. What kind of patients with prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urologic Oncology: Seminars and Original Investigations. Elsevier 2018; 36(12): 505 - 517.

266. Kim N. Chi et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381: 13 - 24.

267. Andrew J. Armstrong et al. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. Journal of Clinical Oncology 37, no. 7_suppl (March 1 2019), 687 - 687.

268. Davis I.D., Martin A.J., Stockler M.R. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019 Jul 11; 381(2): 121 - 131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

269. Boeve L.M.S. et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2018; S0302: 30658.

270. Ost P. et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 2018; 36: 446.

271. Ost P. et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015; 67: 852.

272. Crnalic S. et al. Early diagnosis and treatment is crucial for neurological recovery after surgery for metastatic spinal cord compression in prostate cancer. Acta Oncol 2013 May; 52(4): 809 - 15. DOI: 10.3109/0284186X.2012.705437.

273. L.M.S. et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019 Mar; 75(3): 410 - 418. doi: 10.1016/j.eururo.2018.09.008.

274. Heidenreich A., Fossati N., Pfister D., Suardi N., Montorsi F., Shariat S., B., Gandaglia G., Briganti A., Karnes R.J. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol 2018 May; 1(1): 46 - 53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15.

275. Eisenhauer E.A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228.

276. Smith M.R. et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918.

277. Smith M.R. et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011; 117: 2077.

278. Hussain M. et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378: 2465.

279. Smith M.R. et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018; 378: 1408.

280. Mateo J. et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019 Feb; 75(2): 285 - 293. doi: 10.1016/j.eururo.2018.07.035.

281. Hussain M. et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12: 1868.

282. Taylor C.D. et al. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 2167.

283. Ryan C.J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138.

284. Ryan C.J. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152.

285. Roviello G. et al. Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials. Medicine (Baltimore) 2016; 95: e4636.

286. Shore N.D. et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 2016; 17: 153.

287. Beer T.M. et al. Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017; 71: 151.

288. Beer T.M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424.

289. Graff J.N. et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 2016; 27: 286.

290. Evans C.P. et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016; 70: 675.

291. Tannock I.F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502.

292. Kellokumpu-Lehtinen P.L. et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013; 14: 117.

293. Scher H.I. et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016; 34: 1402.

294. Armstrong A.J. et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2010; 16: 203.

295. Italiano A. et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009; 55: 1368.

296. Horgan A.M. et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol 2014; 5: 119.

297. de Bono J.S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147.

298. Scher H.I. et al. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 1996; 88: 1623.

299. Sartor A. et al. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). J Clin Oncol 2016; 34: Abstract5006.

300. Eisenberger M. et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. J Clin Oncol 2017; 35: 3198.

301. Resnick M.J. et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol 2015; 33: 1078.

302. Parker C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213.

303. Hoskin P. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15: 1397.

304. Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17(9): 1306 - 16. DOI: 10.1016/S1470-2045(16)30173-5.

305. Smith M.R. et al. ERA 223: A phase 3 trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic patients with mCRPC. ESMO Congress Oct 19 - 23, 2018, Munich, Germany; 2018.

306. de Bono J.S. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995.

307. Fizazi K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983.

308. Scher H.I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187.

309. de Bono J.S. et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol 2017; 71: 656.

310. Badrising S. et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014; 120: 968.

311. Zhang T. et al. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. Expert Opin Pharmacother 2015; 16: 473.

312. Antonarakis E.S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028.

313. Attard G. et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol 2018; 36: 2639.

314. de Bono J. et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med NEJMoa1911440 2020. doi: 10.1056/NEJMoa1911440.

315. LYNPARZA (olaparib) US prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.

316. de Bono et al. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Presented at ASCO GU 2020 13th - 15th February. San Francisco, CA. Poster F14.

317. Rexer H. et al. Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)-study AP 93/16 of the AUO. Urologe A 2017 Nov; 56(11): 1471 - 1472. doi: 10.1007/s00120-017-0519-9.

318. Gillessen S. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26: 1589.

319. Aggarwal R. et al. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol 2018; 1: 78.

320. Payne H. et al. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 2011; 29: 593.

321. Pezaro C.J. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014; 65: 270.

322. Ohlmann C et al. Second-line chemotherapy with docetaxel for prostate-specific antigen relapse in men with hormone refractory prostate cancer previously treated with docetaxel based chemotherapy. Eur Urol Suppl 2006; 5: abstract #289.

323. Gillessen S. et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018; 73: 178.

324. Esper P.S. et al. Supportive care in the patient with hormone refractory prostate cancer. Semin Urol Oncol 1997; 15: 56.

325. Белозерова М.С., Кочетова Т.Ю., Крылов В.В. Практические рекомендации по радионуклидной терапии при метастазах в кости. Злокачественные опухоли 2015; 4 (спецвыпуск): 448 - 454. DOI: 10.18027/2224-5057-2015-4s-448-454.

326. Daria Handkiewicz-Junak, Thorsten D. Poeppel, Lisa Bodei, Cumali Aktolun, Samer Ezziddin, Francesco Giammarile, Roberto C. Delgado-Bolton, Michael Gabriel. EANM Guidelines for Radionuclide Therapy of Bone Metastases With Beta-Emitting Radionuclides. Eur J Nucl Med Mol Imaging 2018 May; 45(5): 846 - 859. DOI: 10.1007/s00259-018-3947-x. https://pubmed.ncbi.nlm.nih.gov/29453701/

327. Крылов В.В., Кочетова Т.Ю., Волознев Л.В. Радионуклидная терапия при метастазах в кости: новые возможности. Вопросы онкологии 2015; 61(1): 14 - 19.

328. Крылов В.В., Кочетова Т.Ю., Белозерова М.С., Волознев Л.В. Особенности применения различных радиофармпрепаратов при метастазах в кости. Паллиативная медицина и реабилитация 2015; 4: 26 - 33.

329. Pagliarulo V. et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012; 61: 11.

330. Крылов В.В., Дроздовский Б.Я., Карякин О.Б., Бирюков В.А., Воробьева С.Л., Олейник Н.А. Радионуклидная терапия самарием, 153Sm оксабифором у больных раком предстательной железы с метастазами в кости. Онкоурология 2007; 1: 53 - 58.

331. Dy S.M. et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008; 26: 3879.

332. Hartsell W.F. et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798.

333. Hoskin P. et al. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. J Natl Cancer Inst 2015; 107.

334. Frankel B.M. et al. Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty. Spine J 2007; 7: 575.

335. Dutka J. et al. Time of survival and quality of life of the patients operatively treated due to pathological fractures due to bone metastases. Ortop Traumatol Rehabil 2003; 5: 276.

336. Frankel B.M. et al. Segmental polymethylmethacrylate-augmented pedicle screw fixation in patients with bone softening caused by osteoporosis and metastatic tumor involvement: a clinical evaluation. Neurosurgery 2007; 61: 531.

337. Marco R.A. et al. Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am 2000; 82: 642.

338. Saad F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458.

339. Fizazi K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813.

340. Smith M.R. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745 - 755.

341. Smith M.R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39.

342. Stopeck A.T. et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 2016; 24: 447.

343. Aapro M. et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420.

344. Medication-Related Osteonecrosis of the Jaws, S. Otto, Editor. 2015, Springer-Verlag Berlin Heidelberg.

345. Westhoff P.G. et al. Quality of life in relation to pain response to radiation therapy for painful bone metastases. International Journal of Radiation Oncology* Biology* Physics 2015; 93(3): 694 - 701.

346. Lane J.A. et al. ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prev Res (Phila) 2018 Nov; 11(11): 687 - 696. doi: 10.1158/1940-6207.CAPR-18-0147.

347. Resnick M.J. et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368: 436.

348. Barocas D.A. et al. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA 2017; 317: 1126.

349. Santa Mina D. et al. A pilot randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence after radical prostatectomy: a study protocol. BMC Urol 2015 Sep 16; 15: 94. doi: 10.1186/s12894-015-0088-4.

350. A., A. The effect of pelvic floor muscle training on incontinence problems after radical prostatectomy. American journal of mens health 2018; 12(4): 1007 - 1015.

351. Anderson C.A. et al. Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2015; 1: CD001843.

352. Chen Y.C. et al. Surgical treatment for urinary incontinence after prostatectomy: A meta-analysis and systematic review. PLoS One 2017; 12: e0130867.

353. Pavlovich C.P. et al. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU Int 2013; 112: 844.

354. Philippou Y.A. et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev 2018; 10: CD012414.

355. Dieperink K.B. et al. The effects of multidisciplinary rehabilitation: RePCa - a randomised study among primary prostate cancer patients. Br J Cancer 2013; 109: 3005.

356. Buffart L.M. et al. The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer. Cancer 2015; 121(16): 2821 - 2830.

357. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92: 715 - 727.

358. Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review. Ann Surg Oncol 2015 Dec; 22(13): 4117 - 23. doi: 10.1245/s10434-015-4550-z. Epub 2015 Apr 14.

359. Azhar R.A., Bochner B., Catto J., Goh A.C., Kelly J., Patel H.D., Pruthi R.S., Thalmann G.N., Desai M. Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. Eur Urol 2016 Jul; 70(1): 176 - 187.

360. Baguley B.J. et al. The effect of nutrition therapy and exercise on cancer-related fatigue and quality of life in men with prostate cancer: a systematic review. Nutrients 2017; 9(9): 1003.

361. Hulzebos E.H., Helders P.J., Favie N.J., De Bie R.A., Brutel de la Riviere A., Van Meeteren N.L. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA 2006; 296(15): 1851 - 7.

362. Swarm R., Abernethy A.P., Anghelescu D.L. et al; NCCN Adult Cancer Pain. Adult cancer pain. J Natl Compr Canc Netw 2010; 8: 1046 - 1086.

363. Lin C., Wan F., Lu Y., Li G., Yu L. & Wang M. (2018). Enhanced recovery after surgery protocol for prostate cancer patients undergoing laparoscopic radical prostatectomy. The Journal of international medical research; 47(1): 114 - 121.

364. Shin K.Y., Guo Y., Konzen B., Fu J., Yadav R., Bruera E. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5): 63 - S68.

365. L.M.S., Hulshof M.C.C.M., Vis A.N., Zwinderman A.H., Twisk J.W.R., Witjes W.P.J., Delaere K.P.J., Moorselaar R.J.A.V., Verhagen P.C.M.S., van Andel G. et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019 Mar; 75(3): 410 - 418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25.

366. Bourke L., Homer K.E., Thaha M.A., Steed L., Rosario D.J., Robb K.A. Interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review. Br J Cancer 2014; 110: 831 - 841.

367. Hunter E.G., Baltisberger J. Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol 2013; 32(4): 443 - 456.

368. Frisk J. et al. Two modes of acupuncture as a treatment for hot flushes in men with prostate cancer - a prospective multicenter study with long-term follow-up//european urology. - 2009. - Т. 55. - N 1. - С. 156 - 163.

369. Segal R., Zwaal C., Green E., Tomasone J.R., Loblaw A., Petrella T. Exercise for People with Cancer Guideline Development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017; 24(4): e290 - e315.

370. Boyd C., Crawford C., Paat C.F., Price A., Xenakis L., Zhang W. Evidence for Massage Therapy Working G: The Impact of Massage Therapy on Function in Pain Populations - A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations. Pain Med 2016; 17(8): 1553 - 1568.

371. Mehling W.E., Jacobs B., Acree M. et al. Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage 2007; 33 (3): 258 - 66.

372. Kessels E., Husson O., van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018; 14: 479 - 494.

373. Rief H., Omlor G., Akbar M., Welzel T., Bruckner T., Rieken S., Haefner M.F., Schlampp I., Gioules A., Habermehl D. et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer 2014; 14: 67.

374. Bensadoun R.J., Nair R.G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015; 33(10): 487 - 491.

375. Shen S. et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005; 173: 777.

376. Teeter A.E. et al. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. J Urol 2018; 199: 713.

377. Stephenson A.J. et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973.

378. Loblaw A. et al. Follow-up care for survivors of prostate cancer - clinical management: a program in evidence-based care systematic review and clinical practice guideline. Clinical Oncology 2017; 29(11): 711 - 717.

379. Horwitz E.M. et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 2005; 173: 797.

380. Oefelein M.G. et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995; 154: 2128.

381. Tokas T. et al. A 12-year follow-up of ANNA/C-TRUS image-targeted biopsies in patients suspicious for prostate cancer. World journal of urology 2018; 36(5): 699 - 704.

382. Barry M.J. et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol 1992 Nov; 148(5): 1549 - 57.

383. Cockett A.T.K. et al. Recommendations of the International Consensus Committee concerning Prostate Symptom Score (IPSS) and Quality of Life Assessment; in The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Patronized by WHO. SCI 1994, pp. 553 - 55.